The pain category was effectively flat for Haleon in Q1 2026, with organic growth of -0.3% on £654m of sales (per the Haleon Q1 2026 trading statement and Investing.com Q1 slides coverage).
Within Pain Relief, Advil outperformed the broader market in North America, driven by the "No Pain More Gain" brand campaign. Voltaren and Panadol grew in select geographies but did not offset broader category softness. The pattern is consistent with a softer cold and flu season globally and ongoing private-label pressure in mainstream pain.
Group organic revenue growth was 2.2%, reflecting strength in Oral Health offsetting the weaker Pain and seasonal categories. Haleon reaffirmed full-year outlook.
For commercial teams in UK OTC analgesics: the read is that brand-led innovation and campaign work (Advil, "No Pain More Gain") can overcome category softness, but only on the brands where the activation lands. Voltaren and Panadol UK activity in Q2 will tell whether the playbook translates outside North America. Private-label paracetamol and ibuprofen continue to anchor the value tier in UK pharmacy and grocery, and that pressure does not appear to be easing.
The broader strategic context is that Haleon is now in its fourth post-demerger year (spun off from GSK in July 2022). The OTC-only operating model means category mix matters more than at conglomerate-style consumer health peers, and the Q1 print is a reminder that Pain plus cold and flu cycles drive the headline.